Referencias

1. Melnick JL. Live attenuated poliovirus vaccine. En: Plotkin SA, Mortimer EA, ed. Vaccines. 2nd. ed. Philadelphia: WB Saunders, Inc., 1994: 155-204.

2. Sabin AB. Oral poliovirus vaccine; history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151: 420-436.

3. de Quadros CA, Andrus JK, Olive JM, et al. Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis 1991; 10: 222-29.

4. Salk J, Drucker J. Noninfectious poliovirus vaccine. En: Plotkin SA, Mortimer EA, ed. Vaccines. 2nd. ed. Philadelphia:WB Saunders Co. 1994:205-227.

5. Sabin AB. Paralytic poliomielitis; old dogmas and new perspectives. Rev Infect Dis 1981; 3: 543-64.

6. Tulchinsky T, Abed Y, Shaheen S, et al. A ten year experience in control of poliomyelitis through a combination of live and killed vaccine in two developed areas. Am J Public Health 1989; 79: 1648-52

7. Lash EE, Abed Y, Abdula K, El Tibbi AG, et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6: S467-70.

8. Tulchinski M, Handsher THR,Melnick JL, et al. Immune status to various strain of wild poliovirus among children in Gaza immunized with live attenuated oral vaccine alone compared with a combination of live and inactivated vaccines. J Virol Dis 1994; 1:5-13.

9. Von Magnus H, Oetrsen Y. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984;6:S471-74.

10. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis 1984; 6 (Suppl 2):S457-60.

11. Ogra PL, Faden HS, Duphhy LCA, et al. Effect of prior immunity on the sheeding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991; 164: 191-94.

12. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: a review. Rev Infect Dis 1991; 13: 926-39.

13. John TJ. Experience with poliovaccine in the control of poliomyelitis in India. Public Health Rev 1993; 21: 83-90.

14. Combined Scottish Study. Diagnosis of whooping cough: Comparison of serological test and isolation of Bordetella pertussis. BMJ 1970; 4: 367-9.

15. Mortimer EA. Pertussis vaccine. En: Plotkin SA, Mortimer EA, ed. Vaccines. 2a. ed. Philadelphia: WB Saunders Co., 1994:91-135.

16. Long SS, Welkon CJ, Clark JL. Wide spread silent transmission of Pertussis in families: antibodies correlates of infection and symptomatology. J Infect Dis 1990: 161:480-6.

17. Jenkinson D. Duration of effectiveness of pertussis vaccine:Evidence from a 10 year community study. BMJ 1988; 396: 612-4.

18. Long SS, Linchner HW, Deforest A, Clark LJ. Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 1990; 9: 700-5.

19. Ipp MM, Gold R, Greenberg S, et al. Acetaminophen prophylaxis of adverse reactions following vaccination of infants with diphteria-pertussis tetanus toxoids polio vaccines. Pediatr Infect Dis J 1987;6:721-5.

20. Baraff LJ, Manclark R CH, Cherry DJ, et al. Analysis of adverse reaction to diphteria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 1989; 8: 502-7.

21. Kimura M, Kuno Sakai H. Development in pertussis immunization in Japan. Lancet 1990; 336: 30-2.

22. Feldman S, Perry S, Andrew M, et al. Comparison of acellular (B type) and wole-cell pertussis-component diphtheria-tetanus -pertussis vaccines as the first booster immunization in 15 to 24-months-old children. J Pediatr 1992;121:857-61.

23. Pichichero ME, Francis AB, Marsocci SM,Green JL, Disney FA, Meschievitz C. Safety and immunogenicity of an acellular pertussis vaccine booster in 15 to 20 month old children previously immunized with acellular or whole-cell pertussis vaccine in infants. Pediatrics 1993;91:756-60.

24. Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use - supplementary ACIP statement. recommendations of the Immunization Practices of Advisory Co mmittee (ACIP). MMWR 1992; 4 (RR-1):1-10.

25. Committee on Infectious Diseases, American Academy of Pediatrics. Acellular pertussis vaccines: recommendations for use as a fourth and fifth doses. Pediatrics 1992; 90: 121-3.

26. Mortimer EA. Diphtheria toxoid. En: Plotkin SA, Mortimer EA, ed. Vaccines. 2a. ed. Philadelphia: Saunders, 1994:41-56.

27. Gindler JS, Atkinson WL, Markowitz LE, Hutchins SS. Epidemiology of measles in the United States in 1989 and 1990. Pediatr Infect Dis 1992; 11: 841-6.

28. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323: 160-4.

29. King GE, Markowitz LE, Patriarca PA, Dales LG. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991; 10: 883-7.

30. Markowitz LE, Preblud SR, Fine PE, Orestein WA. Duration of live measles vaccine induced immunity. Pediatr Infect Dis J 1990; 9: 101 -10.

31. Díaz OJ, Valdespino GJ, Zárate AM, Camacho AM, González VM, Chávez SJR. Consideraciones inmunológicas en la prevención del sarampión en México. Bol Med Hosp Infant Mex 1990; 47: 474-81.

32. Lennon JL, Black FL. Maternally derived measles immunity in the era of vaccine -protected mothers. J Pediatr 1986; 108: 671 -6.

33. Markowitz LE, Sepulveda J, Díaz Ortega JL, et al. Immunization of six-month old infant with different doses of Edmonston-Zagreb and Schwartz measles vaccines. N Engl J Med 1990; 322: 580-7.

34. Whittle HC, Campbell H, Rahman S, Armstrong JRM. Antibody persistence in Gambia in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990; 336:1046-8.

35. Gómez DG, Pinzón HR, Candelas B, et al. Parotiditis. En: González SN, Torales NA, Gómez BD, ed. Infectología clínica pediátrica. 5a. ed. México: Editorial Trillas, 1993: 559-60.

36. CDC. Measles prevention: recomendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1989;38: (No.S-9):1-18.

37. Dirección General de Epidemiología, SSA: Incidencia de parotiditis Epidémica Infeccio sa (072) por grupo de edad en los Estados Unidos Mexicanos. Fuente: SS-EPI-1-85.

38. Weibel RE. Mumps vaccines. En: Plotkin SA, Mortimer EA, ed. Vaccines. Philadelphia: W.B. Saunders,1988:223-39.

39. Oran B, Ceri A, Yilmaz H, et al. Hidrocephalus in mumps meningoencephalitis: Case report. Pediatr Infect Dis J 1995;14:724-25.

40. Robson WL, Leung AK, Lemay MD, et al. Parotiditis in diarrhea-associated hemolytic uremic syndrome. Pediatr Infect Dis J 1993;12:257-58.

41. Kim FR, Barr S, Steler H, et al. Clinical mumps vaccine efficacy. Am J Epidemiol 1985;121:593.

42. CDC. Surveillance Summaries; Mumps Surveillance United States, 1988-1993. MMWR1995;44(No. SS-3):1-14.

43. Sassani A, Mirchamsy H, Shafyi A, et al. Development of a new live attenuated mumps virus vaccine in human diploid cells. Biologicals 1991;19:203-11.

44. Sugiura A, Yamda A. Aseptic meningitis as a complication of mumps vaccination. Pediatr Infect Dis J 1991;102:209-13.

45. American Academy of Pediatrics. Mumps. En: Peter G, ed.1994.Red Book: report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics, 1994:330-31.

46. Gugelman R. Why need to continue to immunize against mumps. Soz Praventivmed 1995;40:124-27.

47. Gutiérrez GR, Ruiz GJ, Velasco CL, et al. Investigación de anticuerpos antirrubéola en población infantil y en mujeres adultas de la Ciudad de México. Arch Invest Med 1970; 1:63.

48. Gutiérrez G, Muñoz O, Tapi CR, et al. Seroepidemiología de la rubéola en mujeres mexicanas. Encuesta Nacional Probabilística. Salud Publ Mex 1990; 32:623.

49. Centers for Disease Control. Increase in rubella and congenital rubella syndrome United States. MMWR 1991;40:93.

50. Sifford M, Bates JH. Host determinants of susceptibility to Mycobacterium tuberculosis. Semin Respir Infect 1991; 7: 44-50.

51. Dannenberg AM Jr. Delayed-type hyper sensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 1991; 12: 228-36.

52. Barnes PF, Bloch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324: 1644-50.

53. Griggs SR. Tuberculin skin test: why the Mantoux? Pediatr Infect Dis J 1993;12: 623-4.

54. Clemens JD, Chuong JJH, Feinstein AR. The BCG controversy: A methodological and statistical reapraisal. JAMA 1983; 249: 2362 -69.

55. Broome CV. Epidemiology of Haemophilus influenzae type b infections in the United States. Pediatr Infect Dis J 1987; 6: 779-82.

56. Wegner JD, Hightower AW, Facklam RR, Gaventa S, Broome CV. Bacterial Meningitis Study Group. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis 1990;162;1316 -1323.

57. Ferreccio C, Ortiz E, Aztroza Z, et al. A population based retrospective assesment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr InfectDis J 1990;9:488-94.

58. Macias PM, Saltigeral SP. Meningitis bacteriana, experiencia en el Instituto Nacional de Pediatría 1986-1988. Bol Med Hosp Infant Mex 1993;50:70-1.

59. Kauppi M, Saarinen L, Kayht H. Anticapsular polisaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infants rats. J Infect Dis 1993; 167:365-71.

60. Black SB, Shinefield HR, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61080 children. Pediatr Infect Dis J 1991;10:97-104.

61. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polisaccharide and Neisseria meningitidis outer membrane protein complex. N Engl J Med 1991;324:1767-72.

62. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polisaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62.

63. Paradiso PR, Hogerman DA, Madore DV, et al. Seguridad e inmunogenicidad de una vacuna combinada para difteria, tétanos, tosferina y Haemophilus influenzae tipo b en lactantes pequeños. Pediatrics 1993;92:1-8.

64. Anónimo. Public health control of hepatitis A: memorandum from a WHO meeting. Bull WH0 1995;73:15-20.

65. Hollinger FB. Introduction. J Infect Dis 1995;171(Suppl 1):S1.

66. Riedemann S, Ibarra H, Hochstein-Mintzel V, Reinhardt G, Niedda M, Froesner G. Hepatitis viral en un área rural en Chile. Rev Méd Chile 1987;115:16-18.

67. Ruiz-Gómez J, Bustamante-Calvillo ME. Hepatitis A antibodies: prevalence and persistence in a group of Mexican children. Am J Epidemiol 1985;121:116-19.

68. Bustamente-Calvillo ME, Velásquez-Castillo FR, Padilla-Noriega L, Alvarez y Muñoz MT, Moreno-Altamirano L, Martínez-García M del C, Guiscafré-Gallardo H, Muñoz-Hernández O. Seroepidemiología de la infec ción por el virus A de la hepatitis en comuni dades de la frontera sur del estado de Chiapas. Bol Med Hosp Infant Mex 1986;43:735-41.

69. Kumate J, Alvizouri AM, Isibasi A. Encuesta serológica de hepatitis A en niños de México. Bol Of Sanit Panam 1982;92:494-9.

70. André FE. Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. J Infect Dis 1995;171(Suppl 1):S33-9.

71. Sjögren M, Purcell RH, McKee K, et al. Clinical and laboratory observations following oral or intramuscular administration of a live attenuated hepatitis A vaccine candidate. Vaccine 1992;10(suppl 1):135-7.

72. Ran LA, Wang DZ, Duan QY, et al. Safety and immunogenicity of live attenuated hepatitis A virus vaccine (H2 strain) in humans. Chin Med J 1993;106:604-7.

73. Jilg W, Bittner R, Bock HL, et al. Vaccination aginst hepatitis A: comparison of different short-term immunization schedules. Vaccine 1992;10(suppl 1):126-8.

74. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, André FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171 (Suppl 1): S44-9.

75. Bienzle U, Bock HL, Clemens R, Kru ppenbacher J. Immunogenicity, safety and interference of SB inactivated hepatitis A vaccine with other simultaneously: experience of multicenter trial in Germany (abstract 039). En: Scientific program and abstracts. International Symposium on Viral Hepatitis and Liver Disease (8th Triennial Congress) (Tokyo). Tokyo: Viral Hepatitis Research Foun dation of Japan, 1993.

76. Kallinowski B, Bock HL, Clemens R, Theilmann L. Immunogenität und verträglichkeit eines kombinierten hepatitis-A/B -Impfstoffes. Dtsch MedWschr 1995;120:1426-1429.

77. Subelavsky O. Prevalence of markers of hepa titis B virus infection in various countries: a WHO collaborative study. Bull WHO 1980;58:621.

78. Organización Panamericana de la Salud. La hepatitis en las Américas. Bol. Epid OPS. Washington 1985;6(5):1.

79. Centers for Disease Control. Protection against viral hepatitis: recommendations of the Advisory Committee Immunization Practices (ACIP). MMWR 1990;39(No.rr-2):1-25.

80. Krugman S, Giles JP, Hammond J. Viral hepatitis type B (MS-2 strain). JAMA 1972;217:41.

81. Focaccia R. Hepatite viral. En: Calil Farhat: fundamentos e práctica das imunizaçoes em clínica médica e pediatría. 3a. ed. Sao Paulo: Livraria Atheneu Editora, 1989;44:349.

82. Poovorawa Y, Sanpavat S, Pongpunglert W, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992;11:816-21.

83. Centers for Disease Control. Hepatitis B vi rus. A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Advisory Committee Immunization Practices (ACIP). MMWR 1991;40(No. RR-13).

84. Committee on Infectious Diseases-American Academy of Pediatrics. Universal hepatitis B immunization. Pediatrics 1992;89:795-800.

85. Fuenzalida E, Palacios R, Borgono JM. Anti -rabies antibody response in man to vaccine made from infected suckling-mouse brains. Bull WHO 1964; 30: 431-36.

86. Plotkin SA. Rabies vaccine prepared in human cell cultures: Progress and perspectives. Rev Infect Dis 1980; 2: 433-47.

87. Rabies vaccine adsorbed. A new rabies vaccine for use in humans. MMWR 1988;37:217

88. Yelverton E, Norton S, Obijeski JF, et al Rabies virus glycoprotein analogs: byosinthesis in Escherichia coli. Science 1993; 219:619

89. Bullowa JGM, Wishik SM. Complications of varicella. Their ocurrence among 2534 patients. Am J Dis Child 1935; 923-32.

90. Gardon JD, Chapnick EK, Lutwick LI, Tepperberg J, Kahn M. Group A streptococcal meningitis complicating varicella. Pediatr Infect Dis J 1991; 10: 786-7.

91. Cowan MR, Primm PA, Scott SM, Abramo TJ, Wiebe RA. Serious group A beta-hemolytic streptococcal infections compli cating varicella. Ann Emerg Med 1994; 23: 818-22.

92. Gordon JE. Chickenpox: An epidemiological review. Am J Med Sci 1962; 224: 132.

93. Kourchenco RH, Saltigeral SP, Macías PM. Tratamiento y prevención de la varicela en niños inmunocomprometidos. Rev Enf Infec Pediatr (México) 1995; 34: 48-51.

94. Preblud SR. Varicella complications and cost. Pediatrics 1986;78 (suppl): 728-35.

95. Feldman S, Lott L. Varicella in children with cancer. Impact of antiviral therapy and profilaxis. Pediatrics 1987; 80: 465-7.

96. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yasaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288-1290.

97. Licensure of varicella virus vaccine-live. MMWR 1995;14:264.

98. Diaz PS, Au D, Smith S, et al.Lack of transmission of the live attenuated varicella vaccine virus to immunocompromissed children after immunization of their siblings. Pediatrics 1991;87: 166-70.

99. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty year follow up of protective immunity of the OKA live varicella vaccine. Pediatrics 1994; 94: 524-6.

[ Inicio ]